Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies by Mitchell, S et al.
Henry Ford Health System 
Henry Ford Health System Scholarly Commons 
Center for Health Policy and Health Services 
Research Articles 
Center for Health Policy and Health Services 
Research 
4-26-2016 
Unmet need in the hyperlipidaemia population with high risk of 
cardiovascular disease: a targeted literature review of 
observational studies 
S Mitchell 
S Roso 
M Samuel 
Manel Pladevall-Vila 
Henry Ford Health System, mpladev1@hfhs.org 
Follow this and additional works at: https://scholarlycommons.henryford.com/chphsr_articles 
Recommended Citation 
Mitchell S, Roso S, Samuel M, Pladevall-Vila M. Unmet need in the hyperlipidaemia population with high 
risk of cardiovascular disease: a targeted literature review of observational studies. BMC Cardiovascular 
Disorders 2016; 16:74. 
This Article is brought to you for free and open access by the Center for Health Policy and Health Services 
Research at Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Center for Health 
Policy and Health Services Research Articles by an authorized administrator of Henry Ford Health System Scholarly 
Commons. 
RESEARCH ARTICLE Open Access
Unmet need in the hyperlipidaemia
population with high risk of cardiovascular
disease: a targeted literature review of
observational studies
S. Mitchell1*, S. Roso2, M. Samuel3 and M. Pladevall-Vila4,5
Abstract
Background: The aim of this study was to examine recommended target levels of low-density lipoprotein cholesterol
(LDL-C) for hyperlipidaemia patients at high risk (i.e., with two or more risk factors or coronary heart disease or its risk
equivalents) for cardiovascular disease (CVD); to determine LDL-C targets recommended by guidelines, and to
examine the proportions of patients who do not achieve targeted LDL-C levels in real-world studies.
Methods: Electronic databases were searched: Medline, Medline In-Process, Embase, BIOSIS, and the Cochrane
Library (1 January 2005 to 31 December 2013). Guideline searches were limited to publications in the last 5 years.
There were no geographical or language restrictions.
Results: Seventeen guidelines and 42 observational studies that reported on high-risk hyperlipidaemia patients
were identified. The National Cholesterol Education Program–Adult Treatment Panel III’s LDL-C target levels were
the most common guidelines used for patients with very high hyperlipidaemia. However, between 68 and 96 % of
patients in the studies did not achieve an LDL-C goal <70 mg/dL, except in one study conducted in China
(16.9 %). In high-risk patients, 61.8 to 93.8 % did not achieve a target of <100 mg/dL. Regarding common
comorbidities, patients with concomitant CVD or diabetes were least likely to reach their target LDL-C goals.
Conclusion: In patients with high risk for CVD, the majority of patients do not attain recommended LDL-C goals,
highlighting worldwide suboptimal hyperlipidaemia management and missed opportunities for reduction of the
patients CVD risk. Lipid-modifying management strategies need to be intensified.
Keywords: Hyperlipidaemia, LDL-C, Cardiovascular, Mortality, Review, Observational studies
Background
Hyperlipidaemia is an increase in serum levels of one or
more of the following: low-density lipoprotein choles-
terol (LDL-C), total cholesterol, triglycerides, or both
total cholesterol and triglycerides (combined hyperlipid-
aemia). Patients with hyperlipidaemia are mostly asymp-
tomatic; however, these patients have an increased risk
for cardiovascular disease (CVD), which is the main
cause of premature death, and has been a major cause of
disability and ill health in recent years [1–4].
Lipid-lowering medications include statins, fibrates, and
anion-exchange resins; they are recommended as part of
the management strategy for primary or secondary pre-
vention of CVD in adults with a 20 % or greater 10-year
risk of developing CVD [5]. In large, randomised, con-
trolled trials, statins in particular have been shown to be
effective in preventing coronary heart disease events and
in reducing overall mortality [4, 6–8]. Statins therefore are
recommended as first-line therapy, whereas fibrates and
anion-exchange resins are considered second-line therapy,
or combination therapy when used with statins [9]. Guide-
lines published for Europe [4] and other countries before
2013 [10, 11] recommend a treat-to-goal paradigm for
LDL-C levels. However, despite clear evidence that there
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is a positive association between LDL-C levels and the risk
of cardiovascular (CV) events, there is inconclusive evi-
dence that achieving specific goal levels reduces the risk of
CV events.
A number of published studies have reported that pa-
tients do not achieve LDL-C goals in the hyperlipid-
aemia population [12, 13]; however, to our knowledge
the latest evidence has not been collated in a rigorous
manner. The current study performed a targeted review
of the published guidelines to identify the recommended
treatment targets for LDL-C levels in clinical practice.
This review also assembled the best evidence from re-
cently published observational studies to determine the
proportions of very high-risk, high-risk, and moderately
high-risk patients who do not achieve targeted LDL-C
levels in a real-world setting—that is, in routine clinical
practice—and, if reported in studies, the reasons for not
achieving target levels. This review provides a qualitative
overview of the available data; a meta-analysis was not
performed and a statistical analysis of the results was
not undertaken.
Methods
Literature search and data extraction
This review was performed in an unbiased manner by
using a prespecified protocol and an explicit, reprodu-
cible plan for the literature search and synthesis. A tar-
geted literature search to identify observational studies
was performed in the following databases: Medline,
Medline In-Process, Embase, BIOSIS, and the Cochrane
Library (from 1 January 2005 to 31 December 2013).
Guideline searches of these databases were limited to
publications in the last 5 years in order to evaluate the
most recent practice patterns and recommendations.
Hand searches also were performed, including a search
of the Agency for Health Care Research and Quality’s
National Guideline Clearing House. Systematic reviews
were used to identify primary studies but were not in-
cluded in this review. No limitations on publication
language or geographic perspective were applied. Arti-
cles that were published in a non-English language
were translated as required.
Search terms to identify guidelines and other primary
studies included combinations of free text and Medical
Subjects Headings (MeSH) and consisted of the following
sets of terms:
▪ Health condition of interest (e.g.,
“Hypercholesterolemia”[Majr],
hypercholesterol*[Title], Hyperlipidemias[Majr],
hyperlipidemia[Title], hyperlipidemias[Title],
hyperlipidaemia[Title], hyperlipidaemias[Title])
▪ Suboptimal response (e.g., sub-optim*[Title/Abstract],
suboptim*[Title/Abstract], sub optim*[Title/Abstract],
“goal”[Title/Abstract], “target”[Title/Abstract],
optimum[Title/Abstract], achieve*[Title/Abstract])
▪ Outcomes of interest (e.g., LDL-C goal)
▪ Guidelines and clinical studies (“Practice Guidelines
as Topic”[MeSH], “Guidelines as Topic”[MeSH],
“Practice Guideline”[Publication Type], “Prospective
Studies”[MeSH], “Registries”[MeSH], observational
stud*[Text Word], “Retrospective Studies”[Majr]).
The full Medline literature search strategy is presented
in Additional file 1: Table S1; this search strategy was
adapted for other databases.
Screenings of titles, abstracts, and full-text articles for
eligibility were performed by one researcher; a second re-
searcher performed a quality check of a random selection
of 10 % of all references identified from the searches; any
disagreement was resolved by consensus, with input from
an experienced senior researcher. The following were the
predefined inclusion criteria:
Population: Adult patients with hyperlipidaemia with
moderately high risk, high risk, or very high risk of
CVD
Intervention: No limits applied
Outcomes: Target LDL-C levels recommended by
guidelines; the proportion of patients who did not
achieve the LDL-C targets; and the reasons, if reported
in the study, for not achieving the target LDL-C levels
Study type: Observational studies; clinical practice
guidelines
Exclusions: Studies with a sample size of less than 100
subjects or studies in familial hypercholesterolaemia
Data synthesis
The treatment guidelines obtained from various countries
were used to examine differences among recommended
LDL-C target levels for patients with hyperlipidaemia. Re-
sults of the observational studies generally were sum-
marised quantitatively, using descriptive statistics; due to
the heterogeneity between the included studies a statistical
analysis was not undertaken.
To qualitatively synthesise data from the observational
studies, we summarised data in detailed evidence tables
and figures. The summarised data included information
on the study design; population size; patient characteris-
tics, including risk category definitions (very high risk,
high risk, and moderately high risk of CVD); and results
(i.e., the LDL-C target level recommended for hyperlip-
idaemic patients who are at very high risk, high risk, and
moderately high risk of CVD; the proportion of patients
who do not achieve the LDL-C target levels; and the rea-
sons for not achieving these targets). The definition of
high risk was extracted as reported by the study; gener-
ally high risk was defined as two or more risk factors for
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coronary heart disease (CHD) or its risk equivalents. A
quality assessment of the included studies was not per-
formed because this review did not evaluate comparative
effectiveness and safety of treatments used in the man-
agement of hyperlipidaemia; rather, we evaluated, within
the studies reviewed, the general trends in patients not
achieving LDL-C target goals.
Results
Study identification and characteristics
Searches for guidelines identified 545 records (databases =
533; Internet and hand searches = 12). After the initial
screening of titles and abstracts (level 1 screening), 82 pub-
lications (databases searches = 70; Internet and hand
searches = 12) were selected for full-text (level 2) screening.
Ultimately, 17 publications, describing treatment guide-
lines from more than 20 countries, were included in the
current review. Searches for clinical studies retrieved 1620
records (databases = 1620; Internet and hand searches = 0)
and 42 observational studies that reported data for high-
risk patients (that is, patients with very high risk, high risk,
and moderately high risk of CVD) were included. The vol-
ume of studies included and excluded at each stage of
screening is shown in the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses flow chart [14]
presented in Fig. 1.
Treatment guidelines
The European Society of Cardiology and the European
Atherosclerosis Society (ESC/EAS) guidelines for LDL-C
Fig. 1 Flow Chart for Study Inclusion and Exclusion. PRISMA preferred reporting items for systematic reviews and meta-analyses, RCT randomised,
controlled trial
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target levels for patients with hyperlipidaemia are widely
used in European clinical practice in Austria, Belgium,
Denmark (endorsed by the Danish Society of Cardiology),
France, Ireland, Italy (Nota 13, the prescribing guideline
for hyperlipidaemia, references the ESC/EAS), Poland
(recommended by Polish Cardiology Association), and
Russia. Additionally in Austria, there is a consensus docu-
ment, Lipidkonsensus, prepared by experts from eight
Austrian medical associations [15, 16]. In Finland, the
Netherlands, Norway, Spain, Sweden, Switzerland, the
United Kingdom, and South Africa, experts have devel-
oped, or are planning to develop, country-specific guide-
lines; the recommended LDL-C target levels for various
risk categories in these guidelines varied slightly compared
with the levels recommended in ESC/EAS guidelines
(Additional file 1: Table S2). The new guidelines from the
American College of Cardiology and the American Heart
Association (ACC/AHA) developed in conjunction with
the National Heart, Lung, and Blood Institute do not
recommend a target LDL-C level for treated patients
because, according to the authors, there is a lack of
evidence from clinical trials. Rather, the ACC/AHA guide-
lines recommend intensive treatment options based on
risk assessment and LDL-C levels to reduce CVD events.
In Asia, most countries currently follow the National
Cholesterol Education Program–Adult Treatment Panel
III (NCEP-ATP-III) guidelines.
Recommended LDL-C target levels for patients with varying
underlying risks
Recommended LDL-C target levels for very high-risk
or high-risk patients This review observed that the
risk definitions were not consistently used between guide-
lines. Eleven guidelines recommended target LDL-C levels
for patients with a high or very high risk for CV disease
(Additional file 1: Table S2). For patients with CHD, or who
have two or more CVD risk factors, CHD risk-equivalent
conditions, or diabetes, the recommended LDL-C target
levels ranged from <70 mg/dL (<1.8 mmol/L) to <120 mg/
dL (3.1 mmol/L); the majority of the guidelines recom-
mended a target of <100 mg/dL (<2.6 mmol/L) [11, 15–21].
Two guidelines from Europe [5, 20] recommended a target
LDL-C level <70 mg/dL (<1.8 mmol/L) for very high-risk
patients; the ACC/AHA guidelines [1] recommended treat-
ment with a moderate- or high-intensity statin (depending
on the patient’s 10-year atherosclerotic CVD risk) in pa-
tients with a LDL-C level of between 70 and 189 mg/dL
(1.8–4.9 mmol/L).
Patients with known CVD are at very high risk for CV
events. Long-term treatment to prevent recurrent car-
diac morbidity and mortality and to improve quality of
life in patients who had a prior episode of myocardial
infarction, acute coronary syndrome, angina, stroke,
peripheral artery disease, or peripheral vascular disease,
or who are at high risk of ischaemic cardiac events for
other reasons, such as severe coronary artery stenoses or
prior coronary surgical procedures [22], is discussed as
secondary prevention. Thirteen treatment guidelines
recommended specific LDL-C targets for secondary pre-
vention. The most common target was <100 mg/dL
(<2.6 mmol/L), which was recommended by eight different
guidelines in Asia [17]. For very high-risk patients,
Philippines and Thailand recommend a lower target
level of less than 70 mg/dL (1.8 mmol/L). In the United
Kingdom, the guidelines published by the National
Collaborating Centre for Primary Care and Royal
College of General Practitioners [5] set a target LDL-C
level of ≤77 mg/dL (≤2.0 mmol/L) for adults with clin-
ical evidence of CVD. A broader target of between 66
and 97 mg/dL (1.7 and 2.5 mmol/L) is recommended
by the Norwegian Directorate of Health, for persons
with atherosclerosis or CVD.
Recommended LDL-C target levels for moderately
high-risk patients Eleven guidelines recommended tar-
get LDL-C levels for moderately high-risk patients (those
with no CHD but with ≥2 risk factors) (Additional file 1:
Table S2). The recommended targets ranged from
77 mg/dL (≤2.0 mmol/L) in the Canadian Cardiovascular
Society guidelines [23] to <140 mg/dL (3.6 mmol/L) in
the Japanese Atherosclerosis Society guidelines [11].
Most guidelines recommended a target of <130 mg/dL
(3.4 mmol/L) [15–19, 24].
Proportion of high- or very high-risk patients not achieving
LDL-C targets
Numerous clinical and epidemiologic studies have
shown that an elevated LDL-C level is one of the major
modifiable risk factors associated with the development
of CHD. Of the observational studies that were included
in the current review, NCEP-ATP-III LDL-C targets
were most commonly used, followed by the Canadian
Working Group, and the Third Joint European Task
Force of the European Society of Cardiology; other stud-
ies used country-specific guidelines. In very high-risk pa-
tients, between 68 and 96 % did not achieve an LDL-C
goal of <70 mg/dL, as recommended by the NCEP-ATP-
III guidelines (Fig. 2), with the exception of one study
conducted in China (16.9 %). Most studies found that
most high-risk patients (61.8–93.8 %) did not achieve a
target of <100 mg/dL as recommended by the NCEP-
ATP-III guidelines (Fig. 3); nine studies reported lower
proportions (0.0–47.3 %). For moderately high-risk
patients (Fig. 4) in 10 out of 14 studies, 35.6 to
78.2 % did not achieve the NCEP-ATP-III target goal
of <130 mg/dL. Further, four studies conducted in the
United States reported lower proportions, between 6.6
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Fig. 2 Patients (Very High Risk) Not Achieving NCEP-ATP-III Guidelines LDL-C Level Target, <70 mg/dL (1.81 mmol/L). LDL-C low-density lipoprotein
cholesterol, NCEP-ATP-III National Cholesterol Education Program–Adult Treatment Panel III, US United States. Notes: Treated and untreated patients.
The N represents patients at high risk, a subset of the total number of patients studied. Sources: [29, 35–37, 39, 43–45]
Fig. 3 Patients (High Risk) Not Achieving NCEP-ATP-III Guidelines LDL-C Level Target, < 100 mg/dL (2.56 mmol/L). LDL-C low-density lipoprotein
cholesterol, NCEP-ATP-III National Cholesterol Education Program–Adult Treatment Panel III, US United States. a Primary prevention, 9 months,
women. b Primary prevention, 9 months, men. c Based on 2004 guidelines. d Treated and untreated patients. e Treated patients. Sources: [25, 26,
29, 34–36, 39, 43–51]
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and 24.0 %. Similar results were observed in Ilerigelen
et al. [25] (12.7 %) which was conducted in Turkey.
Three studies that followed the Canadian Working
Group guidelines, using a target of <97 mg/dL
(2.5 mmol/L), reported that between 38.0 and 42.3 %
of high-risk patients did not achieve this goal [26–28].
A further five studies also used a target of <97 mg/dL
(<2.5 mmol/L), as recommended by the Third Joint
European Task Force guidelines, the European Society
of Cardiology, and guidelines from Brazil and
Hungary; 41.7 to 89.7 % patients did not achieve this
goal [29–33].
Proportion of high- or very high-risk patients with con-
comitant conditions not achieving LDL-C targets
Overall, of all of the common comorbidities, patients with
concomitant CVD and diabetes seemed the least likely to
reach their target LDL-C goals (Additional file 1: Table S3).
Concomitant health conditions may have an impact
on hyperlipidaemia patients’ CV risk category and, by
extension, their LDL-C target. This is particularly true
for CHD and other conditions that are classed as CHD
risk equivalents because these are considered to be the
highest risk indicators for CVD, and therefore have
the most stringent LDL-C targets. The studies we
reviewed showed considerable variability in LDL-C
goal achievement for patients with different concomi-
tant conditions (Additional file 1: Table S3). In the
majority of the studies, more than 60 % of patients
failed to achieve the LDL-C target levels. In a 4E-
Registry study [34], the percentage of male patients with
diabetes mellitus failing to achieve goal levels was similar
to the percentage of male patients without diabetes failing
to achieve goal levels (74.7 % vs. 71.7 %). Women without
diabetes mellitus, however, did much better in achieving
their individual lipid goals: 55 % did not attain the goal
levels, compared with 76 % of women with diabetes. How-
ever, achievement of treatment goals in patients with dia-
betes was just as poor as in other high-risk groups in the
4E cohort. In a cross-sectional survey conducted in Asia
[35], >70 % of patients with diabetes, CHD, carotid artery
disease, peripheral arterial disease, metabolic syndrome,
or other multiple risk factors (10-year CHD risk >20 %)
did not achieve the recommended LDL-C targets.
Some studies observed that the number of patients with
CHD who do not achieve their LDL-C targets was not as
high (<50 %); but most studies reported that the majority of
patients did not meet their targets. A similar trend was
observed in patients with other concomitant conditions
such as hypertension, stroke, and kidney disease. One com-
mon theme among the studies that compared concomitant
conditions was that patients with multiple conditions (i.e.,
Fig. 4 Patients (Moderately High Risk) Not Achieving NCEP-ATP-III Guidelines LDL-C Level Target, < 130 mg/dL (3.0 mmol/L). LDL-C low-density
lipoprotein cholesterol, NCEP-ATP-III National Cholesterol Education Program–Adult Treatment Panel III, NR not reported, US United States. Note:
The N represents patients at high risk, a subset of the total number of patients studied. a Based on data from 2003. b Treated and untreated patients.
Sources: [25, 29, 35, 36, 44–53]
Mitchell et al. BMC Cardiovascular Disorders  (2016) 16:74 Page 6 of 10
patients at higher CV risk) were less likely to reach LDL-C
goals than patients with a single condition. Another notable
theme was that, within an individual study, patients in
higher CV risk categories were less likely to reach LDL-C
target goals than patients in lower CV risk categories. How-
ever, it should be noted that patients in higher risk categor-
ies have lower target goal levels.
Potential reasons for patients not achieving target LDL-C
levels
The reasons why patients did not achieve their LDL-C
targets was not consistently investigated nor reported
across the studies included in this review. Of the studies
that did report reasons, only a few conducted univariate
or multivariate analysis to investigate the relationship
between patient-level factors that may have contributed
to failure to reach targets. Patient characteristics such as
gender; age; race; body mass index; and comorbid condi-
tions such as diabetes, CHD, peripheral arterial disease,
and carotid arterial disease are some of the known risk
factors that influence the achievement of LDL-C target
goals. However, it is difficult to reach any firm conclu-
sions because some of the studies report conflicting
evidence.
Two studies, one of which was a large international sur-
vey, reported that males were more likely to attain their
LDL-C target goals than females [36, 37], with a univariate
analysis finding that being female decreased the odds of
attaining the LDL-C goal (odds ratio = 0.62, 95 % CI, 0.39-
0.99; P = 0.043) [36]. Contrary to these findings, two large
studies reported that successful LDL-C goal attainment
was positively associated with being female [29, 38].
A Chinese study found that older age increased the odds
(odds ratio = 1.02; 95 % CI, 1.00–1.05 for every 10 years
increment in age; P = 0.038) of attaining the LDL-C target
goals [36]. Older age was also found to be a multivariate
predictor of successful LDL-C goal achievement in a
worldwide multicenter study [37]. Conversely, a large
study in the US found that older age was negatively associ-
ated with LDL-C control [38]. Similarly, another study
reported that LDL-C goal attainment was significantly re-
lated to an age <40 years [29].
As might be expected, several studies reported that
baseline total cholesterol or LDL-C levels had an in-
verse relationship with LDL-C target achievement, i.e.,
higher baseline total cholesterol or LDL-C was associ-
ated with significantly lower odds of attaining LDL-C
goals, P <0.001 [35, 36, 39]. Baseline CV risk was also
found to influence attainment of LDL-C goals. Two
studies conducted in Asia [35, 39] suggested that goal
attainment was inversely related to baseline CV risk,
i.e., the higher the CV risk at baseline, the less likely
the patients were to reach their target. These findings
were supported by a large multicentre, international
trial, which found that being in a lower risk CV group
was a multivariate predictor of successful LDL-C goal
achievement [37].
Patient adherence has been considered to be a major
factor in the low rate of LDL-C target attainment; higher
adherence to treatment is linked to higher proportions of
patients reaching their targets [35]. Reasons for non-
adherence were cited as patients forgetting to take their
medication or stopping taking their medication when their
cholesterol had returned to normal [33, 35, 40]. A cross-
sectional study in Brazil suggested that non-adherence
was common in the population with scarce financial re-
sources due to the high cost of medication [30]. Improper
communication between health care professionals and the
patients, which was particularly clear among aged patients
or those with poor literacy, was also found to be an im-
portant factor for non-adherence [30].
Whilst current guidelines for treating hyperlipidaemia
provide specific algorithms for the treatment of chronic
conditions, they also present a more complex approach to
lipid management, which requires physicians to make deci-
sions about multiple options for treating each patient. A
cross-sectional survey conducted in the United States [41]
showed that although a significant minority of patients did
not receive a dose increase when one appeared warranted,
approximately 70 % of patients did receive a dose increase
at some point. There was a highly significant association of
several physician attitudes and beliefs with the decision to
increase the statin dose; physicians who believed that “sta-
tins are effective” were more likely to increase statin dose,
whereas those who had an attitude that “close enough to
goal is good enough” were less likely to switch or titrate to
higher statin dose [41]. Of the patients who received an in-
crease in statin dose, 50 % were still not at goal and few
were on the highest doses, suggesting that physicians are
not “treating to goal” [41].
Discussion
In this review, evidence from the observational studies
shows that despite the increasing global awareness of the
need for the management of CV events, more than half of
high-risk patients do not attain the lipid levels recom-
mended by the published guidelines. Although lipid-
lowering drugs such as statins are proven to have beneficial
effects on long-term outcomes, hyperlipidaemia remains
unsatisfactorily managed in routine clinical practice. The
ESC/EAS and NCEP-ATP-III guidelines are the primary
guidelines used in clinical practice around the world; they
recommend a treat-to-goal paradigm. In the United States,
the ACC/AHA’s latest guidelines [1] do not recommend a
target LDL-C level; rather, they recommend intensive
treatment options based on risk assessment and LDL-C
levels. The panel believes that the use of LDL-C targets
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may result in the overtreatment of patients with non-
statin drugs that have not shown to reduce the risk of CV
events [1].
Some studies suggested that achieving LDL-C goals
was inversely related to baseline CV risk [35, 37, 39], al-
though one of the reasons put forward for not achieving
goals is that the target levels are lower for such patients
(<70 mg/dL). Treatment non-adherence also is cited as a
common issue in various studies [27, 30, 33, 35]. It is
thought that non-adherence may be due to scarce financial
resources [30] or to improper communication between the
health care professional and the patient, particularly among
elderly patients and those with poor literacy. In addition,
poor physician adherence to treatment guidelines could
also play a crucial role. Other reasons for poor attainment
of treatment goals can include inadequate dosing, failure to
properly up titrate the dose, not switching to a more potent
drug when necessary, and a lack of follow-up after initiation
of treatment. According to a 4E Registry study in Germany,
treatment, once started, was rarely modified. The statin
dose was increased in only 10 % of patients; leading to the
assumption that doctors are not aware of how to reach
target values [34]. In observational studies, patients and
their physicians select treatment on the basis of clinical
need or preference, which can result in differences in clin-
ical outcomes solely because of differences between those
who receive and those who do not receive a treatment.
These results must be interpreted in consideration of the
relatively high rate of missing data at the follow-up visits. It
is possible that predominantly ‘difficult-to-treat’ or non-
adherent patients were lost. Good management strategies,
appropriate therapeutic approaches, and good patient and
physician adherence to recognised practice guidelines will
be crucial in achieving favourable outcomes. Patients in a
high-risk or a very high-risk category tend to have lower
achievement of LDL-C goals, highlighting suboptimal
hyperlipidaemia management worldwide or even the setting
of unrealistic goals [42]. Patients in higher CV risk categor-
ies tend to have more stringent LDL-C target levels, which
may contribute to failure to achieve target levels. Limited
evidence suggests that the reasons for not achieving target
LDL-C goals include gender, age, comorbidities (e.g., dia-
betes and CV risk), hypertension, baseline LDL-C and total
cholesterol levels, and choice of treatments and dosages.
Further primary studies are needed to rigorously explore
these reasons.
Conclusion
The results of the current review suggest there are sev-
eral unmet needs in treating hyperlipidaemic patients:
the reduction of the patients’ risks for CVD and the con-
sequent reduction of the occurrence of CV events have
confirmed the necessity of intensifying lipid-modifying
management. The failure of large numbers of patients to
achieve LDL-C targets, and specifically the failure of pa-
tients in high-risk or very high-risk categories, to attain
LDL-C goals in a number of countries highlight subopti-
mal hyperlipidaemia management worldwide.
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